A biotechnology company developing stem cell therapies to treat neurodegenerative diseases
Our proprietary technology converts mesenchymal stem cells into NurOwn®, a biological drug delivery system designed to support damaged neurons
NurOwn® cells dampen the immune system and secrete growth factors that help damaged neurons survive.
BrainStorm Cell Therapeutics (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
November 29, 2017BrainStorm's Abstracts on Phase 2 NurOwn® Biomarkers Accepted for Presentation at the International Symposium on ALS/MND in Boston
November 9, 2017New Peer Reviewed Publication Shows That BrainStorm's NurOwn® Has a Unique miRNA Signature
November 2, 2017BrainStorm Strengthens Executive Team: Appoints Eyal Rubin as Chief Financial Officer
BrainStorm is proceeding with a randomized, double-blind, placebo-controlled multi-dose Phase 3 trial that is being conducted at multiple U.S. sites.
For more information on enrollment, contact one of the participating clinical trial sites.
Additional information can be found on clinicaltrials.gov under identifier (NCT number): NCT03280056.